1. Home
  2. ABLV vs VERU Comparison

ABLV vs VERU Comparison

Compare ABLV & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ABLV

Able View Global Inc.

HOLD

Current Price

$1.00

Market Cap

39.9M

Sector

N/A

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.10

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ABLV
VERU
Founded
2015
1971
Country
China
United States
Employees
164
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.9M
40.9M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
ABLV
VERU
Price
$1.00
$2.10
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$22.50
AVG Volume (30 Days)
96.1K
57.5K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$16.70
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.36
52 Week High
$1.77
$4.59

Technical Indicators

Market Signals
Indicator
ABLV
VERU
Relative Strength Index (RSI) 64.21 36.87
Support Level $0.82 $0.36
Resistance Level $1.08 $2.67
Average True Range (ATR) 0.08 0.11
MACD 0.03 -0.01
Stochastic Oscillator 83.81 20.00

Price Performance

Historical Comparison
ABLV
VERU

About ABLV Able View Global Inc.

Able View Global Inc operates as a brand management partner of international beauty and personal care brands in China. It provides full-service solutions covering marketing plan, branding, digital and social marketing, omni-channel sales, customer service, overseas logistics, warehouse, and fulfillment. The firm generates revenue from product sales by distributing and selling cross-border products from various brand owners to Chinese consumers.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: